Share on StockTwits

Amicus Therapeutics (NASDAQ:FOLD) VP Enrique Dilone sold 12,810 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $5.40, for a total transaction of $69,174.00. Following the transaction, the vice president now directly owns 50,000 shares of the company’s stock, valued at approximately $270,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on FOLD. Analysts at Cowen and Company raised their price target on shares of Amicus Therapeutics to $14.00 in a research note on Wednesday. Separately, analysts at Janney Montgomery Scott upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 1st. They now have a $5.00 price target on the stock, up previously from $2.50. Finally, analysts at Leerink Swann upgraded shares of Amicus Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 1st. They now have a $6.00 price target on the stock, up previously from $2.50.

Amicus Therapeutics (NASDAQ:FOLD) traded down 1.64% during mid-day trading on Thursday, hitting $5.41. 5,809,074 shares of the company’s stock traded hands. Amicus Therapeutics has a one year low of $1.77 and a one year high of $5.99. The stock has a 50-day moving average of $4. and a 200-day moving average of $2.85. The company’s market cap is $425.8 million. Amicus Therapeutics also was the target of unusually large options trading on Tuesday. Stock traders acquired 5,148 put options on the stock. This is an increase of 533% compared to the typical volume of 813 put options.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings data on Thursday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.08. Analysts expect that Amicus Therapeutics will post $-0.94 EPS for the current fiscal year.

Amicus Therapeutics, Inc (NASDAQ:FOLD) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.